One-Stop Shop: 18F-Flortaucipir PET Differentiates Amyloid-Positive and -Negative Forms of Neurodegenerative Diseases

Conclusion: SSM/PCA-derived binding patterns of 18F-flortaucipir differentiate between amyloid-positive and -negative neurodegenerative diseases with high accuracy. 18F-flortaucipir PET alone may convey additional information equivalent to that from amyloid PET. Together with a perfusion-weighted early-phase acquisition (18F-FDG PET–equivalent), a single scan potentially contains comprehensive information on amyloid (A), tau (T), and neurodegeneration (N) status as required by recent biomarker classification algorithms (A/T/N).

Source: Journal of Nuclear Medicine - January 19, 2021 Category: Nuclear Medicine Authors: Hammes, J., Bischof, G. N., Bohn, K. P., Onur, O., Schneider, A., Fliessbach, K., Honig, M. C., Jessen, F., Neumaier, B., Drzezga, A., van Eimeren, T. Tags: Clinical Source Type: research